Research Focus

Former Employee. Molecular Pharmacology Program; Research Fellow

Recent additions – View all

1. Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors

   Meeting Abstract

   Lito, P.; Saborowski, A.; Yue, J.; Solomon, M.; Joseph, E.; Fellman, C.; Ohara, K.; Morikami, K.; Miura, T.; Lucas, C.; more...
   Cancer Research (2014)

   Fulltext@MSK | Save
2. Disruption of CRAF-Mediated MEK activation is required for effective mek inhibition in KRAS mutant tumors

   Journal Article

   Lito, P.; Saborowski, A.; Yue, J.; Solomon, M.; Joseph, E.; Gadal, S.; Saborowski, M.; Kastenhuber, E.; Fellmann, C.; Ohara, K.; more...
   Cancer Cell (2014)

   Fulltext@MSK | Save